Equillium, Inc. (0A4D)
LSE 
Summary
0A4D Chart
Equillium, Inc. (EQ) Discusses Mechanistic Insights Linking AhR Signaling and miR-124 in Inflammatory Disease Transcript
Equillium, Inc. (EQ) Discusses Mechanistic Insights Linking AhR Signaling and miR-124 in Inflammatory Disease Transcript
Equillium Links AhR Activation to miR-124 as EQ504 Heads Toward Phase 1
Equillium NASDAQ: EQ Chief Scientific Officer Stephen Connelly outlined new preclinical data during a company webinar focused on the relationship between the aryl hydrocarbon receptor, or AhR, and miR-124, a microRNA implicated in inflammatory disease biology.
Equillium: Multi-Cytokine Platform To Go Beyond Scope Of EQ504 For UC
Equillium (EQ) remains a 'Hold' as it advances EQ504 for ulcerative colitis, with phase 1 trial initiation targeted for mid-2026. Company's Multi-Cytokine Platform enables selective cytokine targeting, aiming to improve efficacy and safety over broad-spectrum inhibitors like JAK/STAT signaling pathways. EQ302, an oral IL-15/IL-21 inhibitor for celiac disease, is positioned for partnering, offering potential future catalysts but remains in early discovery.
Equillium, Inc. (0A4D) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Equillium, Inc. ever had a stock split?
Equillium, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Bruce D. Steel CEO | LSE Exchange | US29446K1060 ISIN |
| US Country | 35 Employees | - Last Dividend | - Last Split | 11 Oct 2018 IPO Date |
Overview
Equillium, Inc. is a pioneering clinical-stage biotechnology enterprise committed to the development and commercialization of innovative therapies for autoimmune and immuno-inflammatory disorders that currently lack sufficient medical solutions. Originally established as Attenuate Biopharmaceuticals, Inc., the company underwent a rebranding to Equillium, Inc. in May 2017, marking a new chapter in its mission. Operating from its headquarters in La Jolla, California, since its incorporation in 2017, Equillium stands out in the biotech industry through its targeted approach to addressing severe diseases across various medical specialties including dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology.
Products and Services
- itolizumab (EQ001)
As the flagship candidate of Equillium, Inc., itolizumab (EQ001) embodies a pioneering first-in-class monoclonal antibody specifically engineered to inhibit the immune checkpoint receptor CD6. This innovative therapeutic approach has shown promise across several clinical trials for treating acute graft-versus-host disease currently in Phase III, indicating a significant step forward in immunotherapy. Additionally, itolizumab has completed a Phase I trial for ulcerative colitis and is undergoing a Phase I trial for lupus nephritis, highlighting its versatile potential in addressing a spectrum of autoimmune diseases.
- EQ101
Targeting the treatment of cutaneous T cell lymphoma and alopecia areata, EQ101 has successfully completed phase 1/2 clinical trials. This advancement signifies Equillium's dedicated efforts in expanding its portfolio to include solutions for dermatological and autoimmune conditions by leveraging cutting-edge biotechnological strategies.
- EQ302
With a focus on gastrointestinal indications, EQ302 is another vital component of Equillium’s therapeutic offerings. This development underlines the company's commitment to broadening its impact on immuno-inflammatory disorders, further emphasizing its contribution to advancing medical science in areas of unmet need.
